Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OX124 is a high-dose, proprietary intranasal formulation of naloxone developed for the rapid reversal of opioid overdose, particularly those caused by highly potent synthetic opioids such as fentanyl. It utilizes Orexo's amorphOX powder-based drug delivery technology, which enables rapid absorption and high bioavailability of naloxone. Clinical studies have demonstrated that OX124 achieves faster and higher plasma concentrations compared to both intramuscular injection reference products and current market-leading naloxone rescue medications at equivalent doses. The product is designed for use in life-threatening situations where opioid overdose is suspected, with the aim to prevent brain damage or death by quickly reversing respiratory depression and other effects of opioids. AmorphOX technology also improves stability and reduces sensitivity to temperature changes during storage. OX124 is protected by patents until 2039[1][3][4][5][6][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OX124.